Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
Motley Fool
Tue, 08/20/19 - 10:39 am
Tags:
AbbVie, Rinvoq, Humira, immunology
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Fierce Pharma
Tue, 08/20/19 - 09:45 am
Tags:
JAK inhibitors, AbbVie, Rinvoq, FDA, Gilead Sciences
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Biopharma Dive
Sat, 08/17/19 - 12:14 am
Tags:
AbbVie, rheumatoid arthritis, drug pricing, Rinvoq
Rinvoq approval bolsters AbbVie's autoimmune portfolio
BioCentury
Fri, 08/16/19 - 11:54 pm
Tags:
AbbVie, FDA, Rinvoq, Upadacitinib, rheumatoid arthritis
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
Thu, 08/15/19 - 11:39 pm
Tags:
FDA, drug approvals, AbbVie, Upadacitinib, Exondys 51, Sarepta Therapeutics, Nabriva Therapeutics, lefamulin, Roche, Rozlytrek
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Fierce Pharma
Wed, 08/14/19 - 07:06 pm
Tags:
Allergan, executive pay, Pharma CEOs, Brent Saunders, AbbVie, M&A
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Fierce Pharma
Tue, 08/13/19 - 11:22 pm
Tags:
AbbVie, Allergan, M&A
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
Tue, 08/13/19 - 11:43 am
Tags:
drug approvals, FDA, AbbVie, JNJ, Novartis, Pfizer, Skyrizi, psoriasis, Vyndaqel, Zolgensma, SMA, Mayzent, multiple sclerosis, Balversa, metastatic bladder cancer
Allergan says it will shed two drugs as AbbVie takeover looms
Pharmaforum
Wed, 08/7/19 - 10:24 am
Tags:
Allergan, brazikumab, Zenprep, AbbVie, M&A
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
Fierce Pharma
Tue, 08/6/19 - 01:21 pm
Tags:
Allergan, AbbVie, Botox, M&A
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Sun, 08/4/19 - 01:02 pm
Tags:
Merck, Keytruda, AbbVie, Humira, Pfizer, Bristol-Myers Squibb, Eliquis, JNJ, Imbruvica
5 Things You Need to Know From AbbVie's Q2 Earnings Results
Motley Fool
Sat, 07/27/19 - 02:03 pm
Tags:
AbbVie, Humira, Venclexta, Imbruvica, hepatitis C, earnings
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
Fri, 07/26/19 - 12:07 pm
Tags:
AbbVie, Humira, biosimilars, Europe, psoriasis, rheumatoid arthritis, Skyrizi
AbbVie stock up 2% after earnings beat
Marketwatch
Fri, 07/26/19 - 12:03 pm
Tags:
AbbVie, earnings
Go or no go? Abbvie, Roche and Kala await key decisions
EP Vantage
Fri, 07/26/19 - 11:04 am
Tags:
FDA, AbbVie, upadacatinib, Roche, Ignyta, entrectinib, Kala Pharmaceuticals, KPI-121, dry eye disease
AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen
Endpoints
Fri, 07/26/19 - 11:00 am
Tags:
AbbVie, Biogen, anti-tau antibodies, ABBV-8E12, progressive supranuclear palsy
Among recent megamergers only AbbVie-Allergan looks like a winner: analyst
Fierce Pharma
Wed, 07/24/19 - 10:08 pm
Tags:
AbbVie, Allergan, M&A, diversification
FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch
Endpoints
Wed, 07/24/19 - 10:07 am
Tags:
Merck, Samsung Bioepis, FDA, Humira, AbbVie, drug launches, biosimilars
Merck's biosimilar to AbbVie's Humira wins FDA approval
Reuters
Tue, 07/23/19 - 07:35 pm
Tags:
Merck, Hadlima, biosimilars, FDA, AbbVie, Humira
Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?
Endpoints
Tue, 07/23/19 - 10:05 am
Tags:
Myovant, uterine fibroids, Relugolix, AbbVie, Elagolix

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.